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Abstract
Background and aims—The etiology of biliary atresia (BA) is unknown. Given that patterns
of anomalies might provide etiopathogenetic clues, we utilized data from the North American
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Childhood Liver Disease Research and Education Network to analyze patterns of anomalies in
infants with BA.
Methods—Two hundred eighty-nine infants who were enrolled into the prospective database
prior to surgery at any of 15 centers participating were evaluated.
Results—Group 1 was non-syndromic, isolated BA (without major malformations) (n = 242, 84
%), Group 2 was BA and at least one malformation considered major as defined by the National
Birth Defects Prevention Study but without laterality defects (n = 17, 6%). Group 3 was
syndromic, with laterality defects (n = 30, 10%). In the population as a whole, anomalies (either
major or minor) were most prevalent in the cardiovascular (16%) and gastrointestinal (14%)
systems. Group 3 patients accounted for the majority of subjects with cardiac, gastrointestinal and
splenic anomalies. Group 2 subjects also frequently displayed cardiovascular (71%) and
gastrointestinal (24 %) anomalies; interestingly this group had genitourinary anomalies more
frequently (47%) compared to Group 3 subjects (10%).
Conclusions—This study identified a group of BA (Group 2) that differed from the classical
syndromic and non-syndromic groups and that was defined by multiple malformations without
laterality defects. Careful phenotyping of the patterns of anomalies may be critical to the
interpretation of both genetic and environmental risk factors associated with BA, allowing new
insight into pathogenesis and/or outcome.
Keywords
birth defects; laterality defects; cholangiopathy; embryonic; nonsyndromic
Introduction
The etiology of biliary atresia (BA) is unknown. In a large series of European infants
reported by Davenport (1), infants with BA were catalogued by two different presentations:
acquired/perinatal/non-syndromic (~90%) vs. embryonal/syndromic (~10%). Infants with
splenic malformation (SM) and associated laterality defects were placed in the latter
category, implying that the pathogenetic and developmental features of the two types of BA
probably differed. In contrast, investigators from Taiwan described the BASM syndrome in
only 0.7% of BA infants whereas a total of 15.4% had other major congenital anomalies,
suggesting different etiopathologies (2).The number of potential etiologies that explain the
pathogenesis of BA has expanded as the sophistication of scientific methods to detect them
has evolved. The viral etiology hypothesis has been supported by a number of reports, such
as the finding of cytomegalovirus in the livers of BA infants (3) and characterization of the
rotavirus-induced murine model of BA (4, 5). Other investigators have suggested an
important role for primary immunologic dysfunction, possibility secondary to maternal
microchimerism (6). One hypothesis unifying the viral and immune dysfunction concept is
that an in utero or perinatal viral infection may trigger an autoimmune attack on the biliary
epithelium (7). Still other groups have utilized new technologies to examine genetic
susceptibility to BA. Leyva-Vega et al (8) reported overlapping heterozygous deletions of
chromosome 2q37.3 in two BA patients; the etiologic significance of these abnormalities is
unclear. A genome wide association study demonstrated a BA susceptibility locus on
chromosome10q24 (9). Recent animal and human evidence support a role for epigenetic
regulation of interferon-gamma signaling in BA (10). Kohsaka et al (11) found human JAG1
missense mutations in about 10% of their BA patients and noted an association of these
mutations with a severe phenotype. Hartley et al (12) suggested that the most likely
etiopathogenetic explanation of BA is that there are multiple mechanisms of biliary injury
leading ultimately to the one common phenotype of obliterative cholangiopathy.
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Given that there well may be more than two forms of BA, we believe that a critical
reappraisal of the anomalies associated with BA could provide useful clues as to the
etiopathogenesis of the disease and have followed the guidelines which the Center for
Disease Control utilized in the National Birth Defects Prevention Network. This Network
was established in 1997 in order provide uniform reporting of birth defects which might then
be linked to a common etiology. Major birth defects were defined by the following criteria:
“a) considered to be a major defect (affecting survival, requiring substantial medical care, or
resulting in marked physiological or psychological impairment); b) usually identifiable in
the first 6 weeks of life (may be extended for some defects); and c) consistently
classifiable.”(13) In an attempt to identify environmental causes of a given disease process
(such as toxins or viral infections) as well as genetic causes, the Center for Disease Control
has followed the principle that careful homogenous case definition is the optimum way to
identify risk factors and that etiologies of disease conditions such as biliary atresia are likely
to be distinct for isolated cases without other major birth defects (our Group 1 – no major
anomalies), cases associated with other major birth defects but not syndromes (our Group 2
– major anomalies without laterality defects) vs. cases associated with stereotypical
anomalies (our Group 3 – Major anomalies with laterality defects (14).
The purpose of this study was to utilize data from the large prospective multi-center study of
BA of the North American Childhood Liver Disease Research Network (ChiLDREN) to
perform a detailed analysis of congenital anomalies associated with BA. A sub-aim was to
determine if certain demographic variables were associated with the subgroups of BA.
Patients and methods
Subjects
Infants with suspected BA were enrolled into a prospective longitudinal study of cholestasis
in infancy (PROBE: Clinicaltrials.gov NCT00061828) prior to diagnostic surgery at any of
15 centers participating in ChiLDREN. The diagnosis of BA was confirmed by
intraoperative cholangiogram and surgical exploration prior to Kasai hepatoportenterostomy.
In addition the central Pathology Committee of the network supported the diagnosis of BA
by blinded review of liver biopsies, coupled with examination of the biliary remnants in
cases where the biopsy was uncertain. Determination of each associated anomaly was made
from information gathered at the time of surgery, by review of imaging and other clinical
studies and by physical examination. When a discrepancy was identified (e.g. no mention of
polysplenia made on ultrasound vs. polysplenia noted at the time of surgery), a three-person
adjudication committee determined the credibility of evidence. After review of all the data
collected on a patient, infants were assigned to one of three groups. Group 1 was isolated
BA (without major malformations and with a single spleen), Group 2 was BA without
laterality defects but with other congenital malformations, including at least one
malformation considered major as defined by the National Birth Defects Prevention Study
(13). Group 3 was BA with one or more laterality defects. These defects included splenic
abnormalities (asplenia, polysplenia, right sided spleen, or a double spleen), cardiovascular
anomalies (dextrocardia, mesocardia, total or partial anomalous pulmonary venous return
[TAPVR/PAPVR], absent or interrupted inferior vena cava [IVC], anomalous/bilateral
superior vena cava [SVC], and/or preduodenal portal vein and gastrointestinal anomalies
(“abdominal heterotaxy,” midline/transverse liver, right sided stomach, intestinal
malrotation, and anomalous or annular pancreas) (15).
All children in this study were enrolled between May 29, 2004 and November 1, 2010.
Written informed consent was obtained from the parent/legal guardian of each patient and
the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as
reflected by approval by the institutional review committees at each site.
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Demographic and Clinical Variables
Extensive demographic information was collected prospectively for each subject. This
information included maternal age, paternal age, parity and fetal exposure to drugs
(including prescribed, over-the-counter, recreational and herbal preparations) and gestational
diabetes. Location of the home during the pregnancy was categorized as rural, urban or
suburban. Family history included the presence of autoimmune diseases among the primary
family and 1st degree relatives and the frequency of autoimmunity in family members was
calculated (percent of patients with at least one first degree relative with autoimmune
disease.) Both mothers and fathers were asked if any first degree relatives had one or more
of the autoimmune diseases listed in Table 1. Information collected about the child included
birth weight, birth length and sequential laboratory tests from the time of presentation to the
evaluation by the specialist. All laboratory tests are reported as measured except that
globulin was inferred by subtraction of albumin from total protein.
Analytic Methods
Descriptive data were summarized by means and standard deviations (sd) for continuous
variables and as percentages for categorical variables. The data were summarized overall, as
well as within each of the 3 BA groups. In addition to the descriptive analyses, several
factors were evaluated for differences across the BA groups. For the continuous variables,
analysis of variance was utilized to assess overall differences amongst the groups. Where the
F-test reached statistical significance (p < 0.1), pairwise comparisons were made for the 3
BA groups to ascertain specific differences. The categorical variables were assessed by chi-
square tests where evidence of general association (p < 0.1) was further explored through
pairwise comparisons of the 3 groups. All analyses were performed using SAS (SAS
Institute Inc. 2008. SAS/STAT® 9.2 User’s Guide. Cary, NC: SAS Institute Inc).
Results
Three distinct BA groups identified
The majority of patients with BA were within Group 1, isolated BA without associated
major malformations (242/289, 84%). Group 2, BA without laterality defects but with at
least one major malformation, encompassed 17 of the 289 BA patients (6%) and Group 3,
BA with one or more laterality defects, encompassed 30 of 289 patients (10%). Table 2
summarizes the most common major and minor anomalies reported by system in all 289
subjects and in each of the 3 groups. Overall, anomalies were most prevalent in the
cardiovascular (16% of subjects), and gastrointestinal (14%) systems and splenic anomalies
(7%). Group 3 patients with laterality defects accounted for the majority of subjects with
cardiac, gastrointestinal and splenic anomalies. Splenic anomalies were noted in 70% of
Group 3 patients.
Group 2 subjects, while also displaying significant cardiovascular (71%) and gastrointestinal
(24%) anomalies, also had significant genitourinary (47%) anomalies which were
uncommon in Group 3 subjects. The most common genitourinary defects found in this group
were cystic kidney and hydronephrosis. Four of the Group 2 patients had vertebral and rib
anomalies but only one had a major musculoskeletal anomaly (longitudinal limb deficiency.)
The cardiovascular anomalies in Group 2 included aortic arch abnormalities, aortic
coarctation, atrial septal defects, patent ductus arteriosus, patent foramen ovale, pulmonary
artery stenosis, pulmonary valvular stenosis, Tetralogy of Fallot, transposition of the great
vessels and ventricular septal defect. Gastrointestinal anomalies included duodenal/jejuna
atresia, esophageal atresia, and imperforate anus. Supplementary Table S1 summarizes the
distribution of the systems with at least one reported anomaly for the 47 individual patients
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in Groups 2 and 3. Supplementary Table S2 summarizes the distribution of specific
genitourinary anomalies across all three Groups.
Demographic variables associated with BA groups
Analysis of demographic variables between groups revealed significant differences in the
age at first evaluation, with Group 1 having a later age at evaluation compared to Group 3
(Table 3). Recreational drug use during pregnancy was reported more commonly in Group 3
compared to Group 1. There was no difference between the 3 groups for mother’s or father’s
age, gender, race, history of familial autoimmune disease, z-scores for birth weight or
length, or rural vs. urban location. For gestational age, the difference across the three groups
was significant (F test p=0.0912). Subsequent pairwise comparison revealed Group 1 infants
tended to be slightly older than Group 3 infants (p = 0.0512). The mean maternal age was
29.2 +/− 6.0 years and the mean paternal age was 31.9 +/− 7.0 years. The incidence of
gestational diabetes was increased in Group 3 compared to Group 1. Interestingly, the
incidence of an autoimmune disease in first degree relatives was substantial – 44% overall,
with no difference between groups. Sixty-three percent of the whole population of BA
infants was white, without differences between the three groups. The race/ethnicity
distribution was relatively even across groups but the small sample size makes it difficult to
compare anything other than white vs. non white.
Clinical laboratory variables associated with BA groups
Table 4 reports select clinical and laboratory variables that were prospectively collected.
While total bilirubin did not differ across the three groups, there was a difference in direct
bilirubin across groups (F test p=0.0693). Group 1 infants tended to have a higher direct
bilirubin values compared to Group 2 and Group 3 though neither of these pairwise
comparison reached significance at the p=0.05 threshold (p=0.0999 and p=0.0654,
respectively). Gamma-glutamyl transpeptidase (GGTP) was similar across the groups.
Alkaline phosphatase was significantly higher in Group 1 compared to Group 2. After
adjusting for age at first evaluation, these laboratory differences across the groups remained
(data not shown).
Total protein and albumin levels were higher in Group 1 compared to Group 3. Alanine
aminotransferase was lower in Group 2. Group 3 was characterized by higher white blood
cell counts and platelet counts vs. the other two groups.
Discussion
In this prospective North American multi-center study of BA, we identified 3 groups of BA
patients. The most common was isolated BA, the perinatal or acquired form of BA without
associated major malformations (Group 1). A second group was identified whereby not only
gastrointestinal and cardiac anomalies were associated with BA in the absence of laterality
defects, but also findings of genitourinary anomalies (Group 2). The most frequent renal
anomalies reported in Group 2 were cystic kidneys or hydronephrosis. The observation that
as many as 16% of children with BA may have heart disease and 3% may have renal
anomalies, makes differentiation from Alagille Syndrome difficult. Likewise, the fact that
infants with biliary atresia may occasionally have cystic kidneys may make differentiation
from infants with polycystic liver-kidney disease a bit of a challenge, although cholestasis is
rare in the latter condition The incidence of clinically significant hydronephrosis in
otherwise healthy newborns is approximately 1 in 600 live births (0.17%) (16, 17). The
incidence of hydronephrosis in BA patients in this study (all within Group 2) was 3 in 289
(1%), an almost 10-fold greater incidence compared to the general population. There is scant
recent literature on genitourinary and musculoskeletal abnormalities associated with BA. A
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case report described an infant with BASM, sacro-coccygeal agenesis, clubfoot, and ano-
urinary incontinence (18). A BA patient with anorectal agenesis and a complicated
urogenital malformation was also described (9). It is known that many genitourinary
anomalies are associated with concurrent vertebral segmentation anomalies (20).
In our study of Group 2 patients with genitourinary and musculoskeletal abnormalities, a
similar association to that previously reported in the literature is suggested. In addition some
of the Group 1 had clinically insignificant rib or vertebral defects. Almost twenty years ago
Carmi et al (21) reported that one-third of their 51 BA patients with major anomalies had
laterality defects but two-thirds had cardiac, genitourinary and musculoskeletal defects not
associated with laterality defects. Our report confirms their findings, extends the spectrum of
renal anomalies observed, and also strongly reinforces the authors’ suggestion that there is
etiologic heterogeneity in BA.
In a large study from England the incidence of splenic anomalies was 10.2% (1), almost
identical to the incidence identified in this study. The investigators from England also
reported similar rates of intestinal malrotation, absent or interrupted IVC and preduodenal
portal vein in patients with splenic anomalies. Fifteen percent of the patients in their series
with laterality defects were born to mothers with diabetes and this association was not found
in their BA patients without laterality defects. Gestational diabetes was observed in 9.9%,
11.8%, and 23.3% of our infants in Groups 1, 2, and 3. Interestingly, the English study also
found a female predominance of 2:1 in patients with splenic anomalies, a finding that was
not identified in our North American cohort. As noted in the paper by Davenport et al (1), in
addition to “BASM,” another term for infants with BA and stereotypical syndromic
abdominal and vascular anomalies is “biliary atresia laterality sequence.” Given that only
70% of our patients with laterality defects actually had splenic anomalies, the latter term
might be preferable in the future to “BASM” to describe this stereotypical group of infants.
The Canadian Pediatric Hepatology Research group has recently reported their analysis of
382 infants with BA and the associated anomalies (22). Forty-four (13%) had associated
anomalies, only 25 (6.5%) of which were associated with SM. The authors concluded that
BA infants with anomalies demonstrated a spectrum of laterality defects and suggested that
the meaning of the acronym BASM be modified to “biliary atresia structural malformation.”
Our conclusions are somewhat similar in that a total of 16% of our infants were in the
anomaly Groups 2 and 3. On the other hand, the main difference between our observations
and those of the Canadian group was that Group 2 infants frequently exhibited major birth
defects of the genitourinary and/or gastrointestinal systems, not considered part of defective
lateralization, suggesting that this group may represent a different etiopathogenesis than
Groups 1 and 3.
Group 3 infants were younger at the time of initial evaluation compared to Group 1. The
associated anomalies in Group 3, especially the cardiac lesions associated with murmurs or
cyanosis, probably brought the patient to medical attention sooner than the infants with
isolated cholestasis.
An unexpected finding was the high incidence of autoimmunity in first degree relatives of
all BA groups (average 44%). The occurrence of autoimmune diseases in relatives provides
circumstantial evidence that a candidate disease (i.e. BA) may be autoimmune in nature
(23). The incidence of autoimmunity in first degree relatives is much higher than that found
in the general population, where autoimmunity rates vary from 2.5-9% (26,27). Importantly,
the incidence of autoimmunity in first degree relatives of BA patients was similar to the rate
of 37-43% identified in autoimmune hepatitis (26) and 25.5% in type-1 diabetes mellitus
(25). This intriguing finding of autoimmunity in first degree relatives of BA patients
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warrants further investigation. The fact that there was no difference in autoimmunity rates
between the three groups suggests that the autoimmune hypothesis of BA may be relevant to
the pathogenesis of all types of BA and is a clue to be pursued in further studies. It is also
possibley that the high incidence simply resulted from our rigorous questionnaire containing
a long list of autoimmune diseases and not being of pathogenetic signficance. We agree that
the lack of differences between groups is not only at variance to explain the autoimmune
hypothesis of Group 1 but also at variance to explain the genetic, non-immune hypothesis of
syndromic BA, in which lower familial rates of autoimmune disease would have been
expected. Possible explanations include the possibility that this hypothesis is incorrect vs.
the immune dysregulation hypothesized for Group 1 BA (27) being atypical from the usual
types of familial autoimmune diseases.
The analysis of laboratory tests revealed no difference in total bilirubin across the Groups
though infants in Group 1 had higher alkaline phosphatase levels and they also tended to
have higher direct bilirubin values. The significance of this observation is uncertain. Group
1 infants tended to be older at time of initial evaluation and thus could be hypothesized to
have a longer duration of obstruction. We explored this possibility by adjusting for age at
first evaluation and the laboratory differences across the groups remained, suggesting age
alone was not responsible. Group 1 infants had higher total serum albumin levels compared
to Groups 2 and 3. It has been reported that newborns have lower albumin levels that
increase with age (28). Both Groups 2 and 3 were younger at the time of evaluation
compared to Group 1 and the younger age at presentation may explain the lower albumin
levels. Furthermore, it is possible that increased protein and albumin losses could be
associated with some of the anomalies present in Groups 2 and 3. Specifically, intestinal
atresias could lead to intestinal protein loss and renal anomalies could result in urinary
protein loss. Finally, higher total white cell counts and platelet counts were identified in
Group 3 compared to the others. The hemodynamics within the spleen in polysplenia are
most likely altered and it is theorized that decreased filtration through the splenic venules
would be associated with decreased trapping and removal of white cells and platelets.
In summary, BA is a heterogeneous disease that is composed of at least three subgroups.
This study identified a group that was defined by multiple malformations including
genitourinary anomalies, reinforcing a similar report by Carmi et al in 1993 (21). Future
investigations are indicated to determine if each of these subtypes is associated with unique
predisposition or etiology.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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List of abbreviations
BA (biliary atresia)
SM (splenic malformation)
IVC (inferior vena cava)
SVC (superior vena cava)
PHTN (pulmonary hypertension)
AV (atrioventricular)
AVSD (atrioventricular septal defect)
LV (left ventricle)
RV (right ventricle)
TAPVR/PAPVR (total anomalous pulmonary venous return/partial anomalous
pulmonary venous return)
TGA (transposition of the great arteries)
VSD (ventricular septal defect)
TEF (trachea-esophageal fistula)
CNS (central nervous system)
KG (kilograms)
CM (centimeters)
GGTP (gamma-glutamyl transpeptidase)
ALT (alanine aminotransferase)
WBC (white blood cells)
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Table 1
Autoimmune diseases in first degree relatives about which parents were queried
Autoimmune liver disease
  Primary biliary cirrhosis
  Primary sclerosing cholangitis
Autoimmune hepatitis
    Autoimmune and connective tissue disease
  Systemic lupus erythematosus
  Raynaud’s syndrome
  Rheumatoid arthritis
  Multiple sclerosis
  Sjogren’s syndrome
  Polymyositis
Autoimmune endocrine diseases
  Insulin dependent diabetes in subjects < 30 years old
  Thyroid disease including hypothyroid, goiter, thyrotoxicosis, and
  thyroid disease type unknown
Autoimmune gastrointestinal diseases
  Ulcerative colitis
  Crohn’s disease
Other unspecified autoimmune disease
Hepatology. Author manuscript; available in PMC 2014 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Schwarz et al. Page 11
Table 2
Frequency of Congenital Anomalies in 289 Biliary Atresia patients by Group
Any
Anomaly TOTAL
GROUP 1
(without major anomalies)
GROUP 2
(major anomalies without laterality defects)
GROUP 3
(laterality defects)
N % N % N % N %
289 242 17 30
Cardiovascular 47 16.3 11 4.5 12 70.6 24 80.0
Pulmonary 4 1.4 1 0.4 1 5.9 2 6.7
Gastrointestinal 40 13.8 9 3.7 4 23.5 27 90.0
Genitourinary 15 5.2 4 1.7 8 47.1 3 10.0
Splenic anomaly 21 7.3 0 0 0 0 21 70.0
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Table 3
Clinical and Demographic Characteristics of 289 Infants with Biliary Atresia
Parameter N Mean +/− SD
or N (%)
P-value vs.
Group 2
P-value vs.
Group 3
Gender (Male vs. Female)
(p=0.4063) 289 135 (46.7%) - -
  BA Group 1 242 109 (45.0%) - -
  BA Group 2 17 10 (58.8%) - -
  BA Group 3 30 16 (53.3%) - -
Birth Weight KG
(p=0.4079) 269 3.15 +/− 0.57 - -
  BA Group 1 223 3.16 +/− 0.54 - -
  BA Group 2 16 3.25+/−0.56 - -
  BA Group 3 30 3.03+/−0.78 - -
Birth Length CM
(p=0.2858) 252 49.8+/−3.6 - -
  BA Group 1 211 49.9+/−3.6 - -
  BA Group 2 15 49.2+/−2.6 - -
  BA Group 3 26 48.8+/−4.0 - -
Gestational Age in Weeks
(p=0.0912) * 271 38.2+/−2.2 - -
  BA Group 1 226 38.3+/−2.2 0.2448 0.0512
  BA Group 2 17 37.6+/−2.1 - 0.7471
  BA Group 3 28 37.4+/−2.3 0.7471 -
Age at First Evaluation (Days)
(p=0.0397*) 288 68.1+/−36.3 - -
  BA Group 1 242 70.4+/−37.6 0.2181 0.0204
  BA Group 2 16 58.9+/−27.8 - 0.6688
  BA Group 3 30 54.2+/−24.7 0.6688 -
Recreational Drug Use During
Pregnancy (p=0.0964 *) 276 10 (3.6%) - -
  BA Group 1 230 6 (2.6%) 0.4325 0.0321
  BA Group 2 17 1 (5.9%) - 0.6041
  BA Group 3 29 3 (10.3%) 0.6041 -
Rural vs. Urban
(p=0.4650) 280 230 (82.1%) - -
  BA Group 1 234 191 (81.6%) - -
  BA Group 2 26 22 (84.6%) - -
  BA Group 3 20 17 (85.0%) - -
Gestational Diabetes (Yes vs. No)
(p <0.0948*) 279 32 (11.5%) - -
  BA Group 1 232 23 (9.9%) 0.8064 0.0298
  BA Group 2 17 2 (11.8%) - 0.3328
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Parameter N Mean +/− SD
or N (%)
P-value vs.
Group 2
P-value vs.
Group 3
  BA Group 3 30 7 (23.3%) 0.3328 -
*Significant at α = 0.1 for differences across BA groups.. Pairwise comparisons were assessed
BA Group 1, n=242 – infants without major anomalies
BA Group 2, n =17 – infants with major anomalies without laterality defects
BA Group 3, n=30 – infants with laterality defects
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Table 4
Selected Laboratory Characteristics of 289 Infants with Biliary Atresia
Parameter N Mean +/− SD P-value
vs. Group 2
P-value
vs. Group 3
Total Bilirubin (p=0.4777) 277 8.43+/−3.48
  BA Group 1 231 8.53+/−3.54
  BA Group 2 17 8.29+/−3.44
  BA Group 3 29 7.70+/−3.01
Direct Bilirubin (p=0.0693) * 167 5.68+/−2.29
  BA Group 1 138 5.87+/−2.22 0.0999 0.0758
  BA Group 2 12 4.74+/−2.49 0.9184
  BA Group 3 17 4.83+/− 2.51 0.9184
GGTP (p=.3921) 262 686.8+/−533.4
  BA Group 1 217 692.2+/−530.6
  BA Group 2 16 802.0+/−669.5
  BA Group 3 29 582.4+/−470.2
Alkaline Phosphatase (p=0.0010) * 272 589.6+/−315.5
  BA Group 1 226 608.3+/−316.6 0.0007 0.0654
  BA Group 2 17 342.5+/−131.6 0.1056
  BA Group 3 29 495.6+/−316.0 0.1056
Total Protein (p=0.0140 ) * 213 6.00+/−0.82 - -
  BA Group 1 176 6.07+/−0.81 0.1121 0.0094
  BA Group 2 15 5.73+/−0.96 - 0.6263
  BA Group 3 22 5.60+/−0.59 0.6263 -
Albumin (p=0.0003) * 268 3.56+/−0.54 - -
  BA Group 1 224 3.62+/−0.51 0.0026 0.0034
  BA Group 2 17 3.22+/−0.66 - 0.5895
  BA Group 3 27 3.30+/−0.57 0.5895 -
ALT (p=0.0299) * 276 150+/−112 - -
  BA Group 1 230 153+/−101 0.0117 0.5534
  BA Group 2 17 83+/−50 - 0.0141
  BA Group 3 29 166+/−189 0.1041 -
WBC (p=0.0121) * 267 13.67+/−4.54 - -
  BA Group 1 223 13.41+/−4.33 0.7998 0.0034
  BA Group 2 16 13.11+/−3.91 - 0.0369
  BA Group 3 28 16.06+/−5.76 0.0369 -
Platelets (p=0.0416) * 266 432.0+/−178.1 - -
  BA Group 1 224 426.1+/−165.2 0.3511 0.0238
  BA Group 2 15 382.1+/−172.9 - 0.0278
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Parameter N Mean +/− SD P-value
vs. Group 2
P-value
vs. Group 3
  BA Group 3 27 508.0+/−256.0 0.0278 -
*Significant at α = 0.1. Pairwise comparisons were assessed
BA Group 1, n=242 – infants without major anomalies
BA Group 2, n =17 – infants with major anomalies without laterality defects
BA Group 3, n=30 – infants with laterality defects
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